University of Maryland awarded $200M for flu vaccine research - Technical.ly Baltimore

Sciences

Sep. 20, 2019 5:14 pm

University of Maryland awarded $200M for flu vaccine research

With one of the largest-ever contracts for the university's Baltimore-based School of Medicine, researchers are looking to strengthen protections against a disease that impacts millions.
University of Maryland School of Medicine.

University of Maryland School of Medicine.

Photo by Wikimedia Commons user Alx bio, used under Creative Commons license.

Researchers in Baltimore will be putting years of vaccine expertise toward strengthening flu shots.

The University of Maryland School of Medicine was awarded a contract worth up to $200 million from the National Institute of Allergies and Infectious Diseases to improve influenza vaccines.

It’s routine to get a flu shot, but the virus is complex and remains far-reaching. About 43 million Americans were impacted in 2018-2019.The goal of the research is to develop a universal influenza vaccine that protects against new strains of the disease and is longer-lasting.

Research is being conducted under a program called Collaborative Influenza Vaccine Innovation Center (CIVICs). Drawing on a team that brings expertise in pre-clinical studies, clinical trials and human challenge studies. A new “clinical core” will be established at the school to evaluate improved flu vaccines, and work toward a universal vaccine.

“While current influenza vaccines have been critical in reducing disease, the virus is constantly changing,” said Dr. Kathleen Neuzil, who is leading the research and is director of the school’s Center for Vaccine Development and Global Health (CVD), in a statement. “The CIVICs program will address the need to develop and test influenza vaccines that protect against new and emerging strains, and ultimately prevent more disease.”

Advertisement

The funding marks one of the largest-ever research contracts awarded to the Baltimore-based University of Maryland School of Medicine, with funding coming over seven years.

For its part, CVD has 40 years of vaccine development expertise. In recent years, researchers there played a key role as trial of a vaccine for ebola were accelerated amid an outbreak in Africa.

-30-
CONTRIBUTE TO THE
JOURNALISM FUND

Already a contributor? Sign in here
Connect with companies from the Technical.ly community
New call-to-action

Advertisement

MF Fire wins $2M to fuel clean wood stove technology

Entrepreneurs, think it’s too early to engage a legal partner? It’s not.

IoT security startup ReFirm Labs raises $2M

SPONSORED

Baltimore

Entrepreneurs, think it’s too early to engage a legal partner? It’s not.

Baltimore, MD

14 West

Qlik Developer

Apply Now

Baltimore, MD

14 West

Senior Qlik Developer

Apply Now

Baltimore, MD

14 West

Lead Qlik Developer

Apply Now

AgeneBio receives $3.4M for development of Alzheimer’s treatment

Frederick’s Veralox Therapeutics raises $5.4M seed round

Healthcare startup Gemstone Biotherapeutics gets Maryland Momentum Fund investment

SPONSORED

Baltimore

Why two eminent Baltimore higher-ed institutions collaborated to create this unique dual degree program

Baltimore

14 West

Senior Business Analyst

Apply Now

Chantilly, VA

Excivity

Android Software Engineer

Apply Now

Chantilly, VA

Excivity

Software Engineer

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!